Diabetes Clinical Trials in Tampa

View 75 new treatments for Diabetes in Tampa, FL, and other areas near me, such as Clearwater, Lakeland and St. Petersburg. Every day, Power helps hundreds of diabetes patients connect with leading medical research.
View 76 trials in Tampa
Filter (76)

Orforglipron vs Semaglutide for Type 2 Diabetes

Eli Lilly Clinic, Tampa + 2 more

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.Show More

Verified

Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

RTA 901 for Diabetic Neuropathy

Biogen Clinic, Tampa + 8 more

This trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.Show More

Verified

Recruiting
Phase 2
Est. 4 - 6 Weeks
Medical Director
Study Director

Amnio Products for Diabetic Foot Ulcers and Venous Leg Ulcers

Stability Clinic, Largo + 1 more

This is a multicenter, prospective, randomized controlled modified multi-platform (matriarch) trial evaluating several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus standard of care alone in the management of nonhealing diabetic foot and venous leg ulcers.Show More

Verified

Recruiting

No Placebo Trial

N/A
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

ILUVIEN® Implant for Diabetic Macular Edema

Alimera Sciences Clinic, Tampa + 2 more

This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Samer Kaba, MD
Study Chair

Metformin for Prediabetes

Research Clinic, Bay Pines + 1 more

This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Gregory G. Schwartz, PhD MD
Study Chair

Metformin vs Insulin for Gestational Diabetes

Research Clinic, Tampa + 1 more

This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Kartik Venkatesh, MD, PhD
Principal Investigator

Rifampin for Osteomyelitis in Diabetics

Research Clinic, Bay Pines + 2 more

The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Mary T Bessesen, MD
Study Chair

Faricimab for Diabetic Macular Edema

Genentech Clinic, Clearwater + 1 more

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
Clinical Trials
Study Director

Aflibercept for Diabetic Retinopathy

Research Clinic, Winter Haven + 1 more

The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were treated in a clinical setting prior to joining the VOYAGE study.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Pentoxifylline for Diabetic Kidney Disease

Research Clinic, Bay Pines + 2 more

Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
David J Leehey
Study Chair
Page 1 of 8

Frequently Asked Questions

How much do diabetes clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do diabetes clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across diabetes trials in Tampa, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for diabetes patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Tampa is research being conducted for diabetes?

Prominent hospitals in Tampa conducting diabetes clinical trials include the University of South Florida Diabetes Center and Tampa General Hospital. As of 2024, there are approximately 17 trials ongoing, with activity concentrated in the central and northern parts of the city.

What promising new drugs are being tested?

In Tampa, diabetes research includes categories like Insulin therapies, Monoclonal Antibodies, and Immunosuppressants. Notable treatments being studied are Afrezza, Dapagliflozin, and the 670G and 770G Insulin Pumps.